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Based on a review of some major technology
assessment agencies dealing with biotechnol-
ogy and bioethics in the USA andfive countries
ofEurope, this study compares the approach in
the different countries. It is found that the
countries of Europe have less national differ-
ences than there are between the USA and
Europe. The core concern in Europe has been
to promote biotechnologies without meeting too
much popular resistance. In Denmark and
some other European countries the will to in-
clude citizens in technological debates has led
to the setting up ofconsensus conferences, in-
volving a lay panel which issues a report at the
end ofthe process.
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T HE EXPRESSION 'technology assessment'comes from the name ofa former (1972-1995)support agency of the United States Congress.
That agency enabled members of the legislative
branch of the US Government to formulate policy
with a better understanding ofthe issues, notably with
respect to scientific and technological developments.
The expression is a little inaccurate in that it does not
do justice to the goal pursued by the founding fathers.
Following the social movements ofthe 1960s, elected
representatives wanted to improve the legislative
branch's ability to understand scientific and technol-
ogical issues, especially so that they could regain
some of the authority Congress had lost to the execu-
tive branch.
Congress was seeking to improve its competence
in every sense of the term. The decline ofparliaments
has been a recurrent theme in political science since
the end ofthe first world war. From this point ofview,
the Act which established the Congressional Office
ofTechnology Assessment in 1972 was not just about
technology. It was a highly significant political event,
whereby a legislative body attempted to recover
power, through supplying its members with compre-
hensive means to master complexity and to express
autonomous judgements. (The agency came to a halt
in 1995 because of Congressional budgetary
restrictions. )
The idea immediately drew interest in Europe as
well. Similar organisations were put in place during
the 1980s in France, the Netherlands, Denmark,
Germany, the United Kingdom, and the European
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Parliament. Italy, Finland and Greece have joined the
group quite recently, in 1996. The mere fact that the
number of such technology assessment institutions
has been growing suggests that a basic challenge of
contemporary society is perceived in various places.
Rapid advances of science and technology clearly
have an impact on everyone's life.
However, how can we relate science and technol-
ogy to politics and democracy? These issues SeelTI to
belong to completely different worlds, based on
different values, different reward systems, different
actors, different languages. While technology assess-
ment is, explicitly or implicitly, expected to bridge the
gap between those differences, the task may prove
more difficult in practice than in theory.
A detailed history of the various institutions has
been dealt with elsewhere (Bimber, 1996; Mironesco,
1997). One potentially interesting piece of inform-
ation is still missing: there is no systematic research
about the implementation ofthe assessment studies in
the policy-making process, even though there is some
evidence about the ways that legislators used the
information produced by the agencies (Birnber, 1996,
pages 25--40).
Nevertheless, aSSeSS111ent studies deserve atten-
tion: they express questions and answers formulated
so far, in various countries, to take up serious
challenges of contemporary politics. Is democracy
affected by the growing power of experts? Is it influ-
enced by a (hypothetical) decline of parliaments?
What sort of message should be considered as objec-
tive, accurate, relevant information for elected
representatives, in such a way that they will be more
likely to make informed decisions? Studies illustrate
tentative answers to these questions.
This paper is based on a review of some major
technology assessment reports dealing with biotech-
nology and bioethics, published since the end of the
80s, in the United States and Europe. As far as Europe
is concerned, the review will be limited to the five
countries which are members of the European
Parliamentary Technology Assessment (EPTA)
network ---- Denmark, France, Germany, the Nether-
lands, and the UK --- and to the assessment unit of the
European Parliament which is also a member of that
network.
The United States
"O'TA's role is neither to pr01110te nor to dis-
courage the development or the application of
any particular technology or legislation, but
rather to help Congress determine whether or
when some form ofFederal government partici-
pation may make sense. O'TA identifies and
clarifies options; exposes misleading, unsup-
portable, or incorrect information; and works to
raise the level of understanding in the debate
about expensive and controversial issues."
(0'[A, 1993a).
328
From the mid-Sus on, OTA produced about ten re-
ports on biotechnologies. The topics were broad and
varied. They dealt with: commercial biotechnology in
an international perspective; changing agriculture;
basic research (Genome project); the dairy industry;
biomedical -laws and ethics. The best known reports,
in the US and abroad, are probably a series which was
published in 1987 and 1988, under the title New
Developments in Biotechnology, Five volumes have
been produced: 1. Ownership ofHuman Tissues Glut
Cells rorA, 1987a); 2. Public Perceptions of
Biotechnology rorA, 1987b); 3. Field-testing Engi-
neered Organisms (OTA~ 1988a); 4. U,S, Investment
in Biotechnology (OTA, 1988b); 5. Patenting Life
(OTA, 1988c). By the beginning of the 90s, the US
Congress was the most widely informed legislative
body in the world, at least potentially.
If ()TA's role was neither to promote nor to dis-
courage the development or the application of any
particular technology, what vvas its role? 13y declaring
that it was limited to identifying options, providing
accurate information, working to raise the level
of understanding in the congressional debates, the
agency adopted a modest tone to assert a not-so-
modest mission. The decision-making role was left to
congressmen, while impartiality was entrusted to ana-
lysts, who were supposed to be neutral in a highly
partisan arena. The analysts strove to translate their
knowledge to answer different or even contradictory
questions, and to enlighten equally parties and COIll-
mittees having different interests.
Let us illustrate this with one report of The New
Developments in Biotechnology Series. OUf choice is
not arbitrary, since this example was picked up by the
congressmen themselves as a good report (()TA,
1993c). Ownership 0.( Human Tissues and Cells
(OTA, 1987a) deals with scientific, economic and
legal issues. It begins by giving simple but clear
definitions and explanations about the revolution in
biological technology since the 70s, Three broad
classes of basic technique are reviewed: tissue and
cell culture; cell fusion to produce antibodies; and
recombinant DNA.
However, the report is not designed to teach a
course on biology. It tackles a novel and quite puz-
zling question: who owns human cells? The human
source of the original tissues and cells? The scientist
who developed the cell line? The firm (pharmaceuti-
cal, oil and chemical, agricultural ... companies)
actively engaged in biotechnology research and
commercial product development?
The argument unfolds along lines showing that
there are indeed various human actors sharing an
interest in dealing with such a question. This is the
added value. As far as scientific and technical inform-
ation is concerned, the report gives only the bare
necessities. In fact, it is the rest of the text which is
illuminating for politicians or citizens. The analysis
presents disputes over ownership of tissues and cells,
without taking sides; it lays out detailed arguments in
favour or against specific answers.
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The end result of the story told in Ownership is to
bring biotechnology back down to earth. The reader
realises that the issue may be very mundane, that it is
possible to debate and take decisions about it without
having a PhD in biology, that the problem is at the
same time new and old, as issues relating to ownership
and property have been part ofthe political agenda for
ages.
Another aspect that should be underlined is that the
procedure is meant to clarify choices for elected rep-
resentatives, not to solve problems on their behalf.
Ownership has been criticised on the grounds that the
basic question asked by the report is not answerable
by analysis; OTA was therefore guilty of asking
wrong questions (Woodhouse, 1992, pages 23-24).
This is an unfair comment and a rather unsafe mis-
conception. OTA did ask a good question, philosophi-
cally speaking. It did not answer it, because it
considers that answers (that is, choices, decisions)
belong to elected legislators, after they have been
properly informed.
Such a division of work between legislators and
analysts became apparent, to a certain extent, in
bioethics as well. OTA's Biomedical Ethics in U.s.
Public Policy appeared in 1993 as a background paper
(OTA, 1993b). Its distinctive feature was the secular
tone adopted all along. It started from "the need to
bring the perceived chaos of biology and medicine
into the order of principle" (OTA, 1993b, page 2).
OTA's conviction was that bioethics is a field that
involves professionals of many backgrounds
(philosophers, theologians, attorneys, clinicians, re-
searchers ...). No one individual or profession can
represent the breadth of perspectives on the topic.
Bioethics was clearly not understood as a new spe-
cialisation, or a new scientific and technical develop-
ment that should be explained to uninitiated
congressmen or citizens. What was the assessment
function in that context?
The study was conducted to "assist Congress in
determining possible approaches to examine policy
problems with biomedical and ethical dimensions"
(OTA, 1993b, page 3). More specifically, Congress
was supposed to decide at some point whether or not
to create a new Federal bioethics body. The request
sought to obtain clarification about options, from that
point of view. This is why the study was, in fact, a
review of the history ofprevious broad-based Federal
The US Office of Technology
Assessment's job was practical and
down to earth: to analyse the reasons
for success or failure of previous
trials - it never tackled issues of
finding moral solutions to complex
policy matters
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bioethics initiatives. Four ofthese were reviewed: two
were located in the Department of Health, Education
and Welfare; a third was an independent executive
branch commission (the President's Commission for
the Study ofEthical Problems); the fourth was located
in Congress. None had survived very long (two to four
years).
OTA's job was practical and down-to-earth: to
analyse the reasons for success or failure of such
trials. It never tackled issues of finding moral solu-
tions to complex policy matters. Requesters and ana-
lysts were engaged in striving to learn lessons, as
objectively as possible, from past experience. They
were involved, so to speak, in a process of self-
analysis. In addition, OTA's study was meant to learn
lessons from abroad. The appendix is a catalogue of
international bioethics initiatives. In 1992, OTA con-
ducted a survey of bioethics and related individuals
in government offices, in 35 countries.
This fact-finding thought process, combined with
a search fOF self-analysis and self-reliance, contrib-
uted a lot to the secular tone ofthe approach. Actually,
the approach did not appearin the 90s as ifby magic.
Growing awareness of the human capacity to influ-
ence living processes had aroused emotions, on both
sides of the Atlantic, at the end of the 70s.
In the United States, a secular authority appeared
quickly in the foreground, with regard to the debate
over the granting ofpatents to genetically engineered
organisms. In 1980, the Supreme Court decided in
Diamond v, Chakrabarty that those organisms were
indeed patentable (Plein and Webber, 1992, pages
135-139).
The question was not: is patenting life morally
acceptable? but: is it constitutional? This is self-
analysis, again. The Supreme Court's argument was
that the US Constitution is meant to protect human
ingenuity, ant that "although laws of nature, physical
phenomena, and abstract ideas are not patentable,
Chakrabarty's micro-organism was a product of hu-
man ingenuity" (OTA, 1988d, page 8).
This was a public and authoritative recognition that
human knowledge had reached a turning point. By
doing so, the Supreme Court also emphasised Con-
gress' responsibility for dealing with those issues.
The division ofpower and the secular approach seem
to belong to the same culture. This process was also
described at length in the 1988 report Patenting Life
(OTA, 1988c).
European Union technology assessment
Not every member state of the European Union is
equipped with a special agency of technology assess-
ment. Taken in chronological order of creation, those
that exist are:
• the French Office Parlementaire d'Evaluation des
Choix Scientifiques et Technologiques, OPECST
(1983);
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• the Dutch Netherlands Organisation for Tech-
nology Assessment, NOTA, now the Rathenau
Institute (1986);
• the Danish Teknologinaevnet, now Teknologi-
radet (1987);
• the British Parliamentary Office of Science and
Technology, POST (1987); and
• the German Buro fur Technikfolgen-Abschatzung
beim Deutschen Bundestag, TAB (1989).
These agencies are loosely co-ordinated in the Euro-
pean Parliamentary Technology Assessment (EPTA)
network, created in 1990. Also a member of the
network, the European Parliament's Scientific and
Technological Options Assessment (STOA) pro-
gramme was created in 1987.
Denmark
The Danish Board (now Council) of Technology
(DBT) has been involved in various activities in the
biotechnologies. From 1987 to 1992, it administered
the TA part of the Danish research and development
biotech programme. It adopted a pluralistic strategy
and produced videos, books, reports, booklets aimed
at different target groups and parties.
It collaborated with trade unions on a project in
which workers from various branches of industry
assessed the impact of biotechnologies on working
life. It conducted surveys on public opinion. It re-
viewed literature and interviewed opinion makers and
central actors in the debate on ethical aspects in USA,
Germany and England. It also organised consensus
conferences (DBT; 1993). The following are some
detailed examples.
National research capacity
In 1991, the Board reported on Research and Dev-
elopment in Danish Biotechnology. This evaluation
of the national research capacity focuses on "new
biotechnology", that is, derived from molecular
biotechnology (recombinant DNA-techniques, cell
fusion, cell and tissues cultures). It deals with the
question: what is the balance between capacity and
needs? Three quarters of the biotechnological re-
search capacity is located in the private sector, one
quarter belongs to the public sector, which concen-
trates on basic rather than applied research. As far as
needs are concerned, the project underlines that re-
search is too limited in plant and animal techniques,
in relationship to environmental problems, or in areas
of special interest for developing countries.
From this, the report concludes that Denmark
should specialise, in order to be competitive on the
international scene. It should provide for new busi-
ness activities, mainly in environmental protection
and/or in response to the demands of developing
countries. Too little is known about how to use recom-
binant DNA to produce cleaner technologies, and
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progress can be made in vaccine and plant research as
well. This is how Danish research could participate in
international co-operation more efficiently (DBT,
1991).
Environment
One year later, the Board reported on Biotechnology
in the Environmental Field. The project had several
objectives: to evaluate major environmental prob-
lems, but also to assess legislative problems related
to the use of biotechnologies in Denmark; to review
literature and to interview specialists on how biotech-
nology may be viewed as a green technology; to look
for possible ways of promoting such a technology in
the country.
The analysis deals first with an overview of how
biological techniques could be helpful in cases of air,
water and soil pollution. It then underlines that air
pollution, caused by energy production and traffic,
will not be easily solved; in addition, the three
types of pollution are of a local nature, and therefore
national initiatives may not seem very convincing.
Nevertheless, there are some areas of interest, one
of which is agribusiness. Pesticides, fertilisers, ma-
nure and so on are sources of pollution: environ-
mentally suitable production may be developed,
based on, for instance, microbial crop spray and
biotechnological crop improvement. Another field
for progress is waste water: here the effort should
be better co-ordinated. In soil treatment, micro-
biological degradation of harmful substances is
supposed to be an inexpensive and environmentally
friendly method (DBT, 1992a).
Consensus conferences
The Board did not deal with research and develop-
ment only. Within the European parliamentary TA
network, it is mostly famous for having formalised
debates involving ordinary citizens in the assessment
process. The debates are called consensus confer-.
ences and take place between a panel of experts and
a panel of lay people (about 10-15 people in each
panel). The lay panel is neither representative of the
entire population, nor of the Danish Parliament. It is
selected by the Board, according to criteria such as
age, sex, place of residence, occupation and educa-
tional background.
At the end of the sessions, the lay panel is expected
to report its views publicly. The Parliament may then
take them into account. The Board has arranged con-
sensus conferences on key topics. The following are
detailed examples.
In April 1987, a conference was held, in co-
operation with the Society of Danish Biologists, on
Genetic Technology in Industry and Agriculture. The
lay panel presented its conclusions in a short docu-
ment. It stressed that genetic engineering is very
different from traditional biotechnology as it was
practised formerly in agriculture and industry: it is
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now possible to combine genes "across the natural
species barrier, endangering or weakening the natural
evolution.
Danish lay people believe that this challenges the
ethics; they wonder whether human beings, as part of
the created world, have an unconditional right to
intervene in it. A majority ofthe panel accepts genetic
engineering, provided that it is strictly controlled and
designed to be a service for mankind. A minority
wants it to be completely banned.
The whole panel agrees to prohibit genetic engi-
neering on animals. They also consider that research
on risks is inadequate and should be improved. They
finally suggest the creation of an ethical council con-
sisting oflay people only; they express their hopes for
an independent information programme to help citi-
zens to understand those issues better; they call for a
more critical attitude towards industry which must be
held responsible for any hazardous consequences of
its products (DBT, 1987).
In November 1989, another consensus conference
was held in co-operation with the Research Commit-
tee of the Danish Parliament. The topic was the Ap-
plication of Knowledge gained from Mapping the
Human Genome. To begin with, the Board reminded
the panel that mapping the human genome has be-
come a scientific goal all over the world, and that the
United States and Japan have launched large-scale
programmes on the subject. In addition, the European
Union Council of Ministers is considering a proposal
from the European Commission about a joint Euro-
pean programme, as an answer by the Union to the
large foreign projects.
The end result of this international research should
be an increased quantity of information about risks
and dispositions for diseases, gene profiles, prenatal
diagnosis, screening of the adult population, crime-
solving, and so on. The question asked of the Danish
lay panel was therefore: how should we use the in-
creased knowledge about human genes? (DBT, 1989,
page 2).
Generally speaking, the panel approves of knowl-
edge used to cure diseases. Nevertheless, a majority
has strong reservations about systematically screen-
ing the population which will only result in causing
fear and anxiety. They ask for the establishment of a
tribunal to provide politicians with advice. They rec-
ommend the drafting ofa list indicating for what kind
of genetic aberration prenatal diagnosis should be
possible. The panel fears the risk of eugenics, in so
far as people might want to be tested for illnesses that
are not serious; they want a popular debate on the
meaning of 'normality' .
On the other hand, the panel recommends legisla-
tion to forbid genetic analysis from becoming the
basis for the assessment of a person, be it in relation-
ship to employment, insurance or retirement. As far
as the scientific prestige of the project is concerned,
the panel is convinced that human genome analysis
can result in important developments, but they insist
that it is developed in harmony with the ethical and
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When releasing technological animals
into nature, extensive risk analyses
must be performed; the long-term
consequences of consuming food
produced by such animals are not
well known, so labelling these food
products is a reasonable demand
cultural values of the population. This is why the
information level and the popular debate must be
strengthened. Finally, the panel feels that basic re-
search should focus on improving knowledge about
the interaction between heredity and environment
(DBT, 1989, pages 5-7).
In September 1992, the Board arranged a consen-
sus conference, in collaboration with the Research
Committee of the Danish Parliament, on Techno-
logical Animals. This title refers to the product of
techniques interfering with the gametes or the embryo
of an animal. First of all, information was provided to
the lay panel. Technological animals may be used in
the agricultural, fishing or pharmaceutical industry;
they may also be used for research purposes. They
contribute to a field ofbiotechnology which is becom-
ing increasingly important. However, the public atti-
tude to this field has been rather negative. The
conference was meant to diffuse interest and knowl-
edge, and to stimulate public debate on the topic.
The lay panel concluded that interest groups and
ordinary citizens should, to a greater extent, be repre-
sented in councils and boards where regulations are
being established, and that they should all have access
to information. As far as the economy is concerned,
the panel recognises that it may be unavoidable to pay
a licence fee (for instance, to cover the cost of re-
search) and that the fees may have a negative impact
on products costs; a possible alternative is toincrease
research and development in ecological farming.
In relation to patents, though, the lay panel under-
lines that the Danish Parliament has already decided
to prohibit the patenting of animals: considering that
patenting life is not acceptable, the panel agrees with
Parliament's decision and wants it to be promoted in
international negotiations. When releasing techno-
logical animals into nature, it is necessary to perform
extensive risk analyses. In the same vein, since the
long-term consequences ofconsuming food produced
by technological animals are not very well known,
labelling those food products is a reasonable demand.
With respect to ethics and values, the panel wishes
to make sure that animals do not suffer and that
researchers take animal welfare into account. If alter-
native methods are available, these should always be
preferred, although it seems reasonable and ethically
acceptable to produce technological animals to try to
cure serious diseases, such as cancer (DBT, 1992b).
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A's far as the political impact of these consensus
conferences is concerned, as a consequence of the
1987 conference, the Danish Parliament decided not
to fund animal gene technology projects in the
bioteclmology research and development programme
1987-1990. The same Parliament decided to forbid
the use of genetic testing for recruitment and insur-
ance claims, as a consequence of the 1989 conference
(Kluver, 1995, page 44).
The Netherlands
The Dutch TA agency, formerly designated by the
acronym NOTA, became the Rathenau Institute in
1994. With respect to biotechnologies, this agency
interprets its mission in terms of both discussion
promoter and information provider. When N01~A
was founded, in 1986, its task was "to draft and to
realise a programme of technology assessment re-
search"; it was also aimed at providing the Minister
of Education and Sciences with advice on matters
relating to the integration of science and teclmology
in society.
Its relationship to Parliament was indirect; it was
not clear, in the original charter, that NOTA should
focus its work on the .legislative body. At the begin-
ning of the 90s, there was a consensus to stay at a
certain distance from the Parliament (Sterrenberg,
1993a). Nevertheless, studies also display inform-
ation or policy options for the Dutch Parliament.
Engineered organisms
In 1988, NOTA and the Dutch Ministry of Economic
Affairs organised workshops on the introduction of
genetically engineered organisms into the environ-
ment. One of these was based on the "Field-testing
Engineered OrganisIns report published by the
American O'TA (1988a). The participants in the vari-
ous debates were government representatives, repre-
sentatives of industry and of biotechnological
research, and representatives of so-called "societal
groups" (such as fanners and consumers).
The experiments led the NOTA to conclude that
members of organisations with divergent interests
tend to have different interpretations of the term
'risk'. Nevertheless, the confrontation of different
actors did not lead to a polarisation of standpoints, as
S011le people of industry had feared. At that point, the
workshops did not have any influence on parliament-
ary decision-making about regulations; political in-
terest in the subject was low (European Congress on
Technology Assessment, 1992, pages 263-272).
Genetic engineering on animals
At the beginning of the 90s, NOTA dealt with another
issue at great length: the genetic engineering on ani-
mals. This subject had given rise to various contro-
versies. The agency had noticed that there "vas no
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consensus on the conditions that should be met for this
technology to be accepted. On the other hand,
progress in this area was rapid; reflection and debate
were urgent.
In 1990, a publication dealt with Ethics Glut gen-
etically modifiedanimals (N01"'A, 1990). The authors
tackled two questions: is the issue really new? is it
morally acceptable? While it was admitted that hu-
manity's use of animals is not something new, the
authors also underlined that today's technology
makes it possible to take the genetic material from one
species and transplant it into another. Life processes
appear therefore to be programmable by humanity in
an unprecedented way.
There is no consensus as to the acceptability of
such a development. Some people tend to accept
genetic engineering without any restrictions, some
would reject it on principle, while still others would
accept it under certain conditions. To assess the ethi-
cal acceptability of genetic engineering on animals,
the authors suggest first admitting that animals have
an "intrinsic value", and then to answer questions
such as: does the aim justify an infringement of the
intrinsic value? is the aim likely to be achieved? are
there any alternatives for achieving the same aim?
(NOTA, 1990, pages 117-120).
A part of the publication also discussed how and to
what extent the government can include ethical con-
siderations in its policy. It was stated that both laissez
faire and ideological interference were to be avoided.
'[a get more insight on that topic in the near future, a
research agenda based on a number of ethical ques-
tions was set up a little later (Sterrenberg, 1993b).
Environment
In 1991, NC)TA dealt with the introduction of Gen-
etically Modified Organisms in the Environment. In
fact, this working document presented the results of
interviews with different people (researchers, legisla-
tors, businessmen, farmers, environmentalists,
church and consumers groups) about a specific
experiment. FrOTIl their reactions, NOTA drew up a
set of questions which may be relevant for official
approval procedures. Because a large part of the
discussion dealt with ethics, values and priorities,
NO'fA underlined that "skills which are necessary for
a discussion about moral questions require extra
attention" (NOTA, 1991b, 135).
Patentable animals
In 1991 , NOTA (1991 a) also prepared a report on
Patentable Animals for Parliament. The issue had
become important since 1988, when the European
Commission launched a draft directive for the legal
protection of biotechnological inventions, including
animal material. The European Patent Convention of
1973, ratified by ten European member states includ-
ing the Netherlands, excluded varieties of animals
from patents (although patents were granted on
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micro-organisms, micro-biological methods and ani-
mal and cell lines in the production of medicines and
vaccines).
In fact, the European Patent Convention was open
to more than one interpretation. By introducing the
draft directive, the European Commission wanted to
reach a consistent policy on patent granting and har-
monise national legislation. The directive was also
justified on the grounds of the competition between
.biotechnology industries in the European Union, the
United States and Japan (NOTA, 1991a, pages
55-56).
The Netherlands Industrial and Agriculture
Biotechnology Association was ofthe opinion that the
European directive did not go far enough. Other
groups (consumers, farmers, environmentalists) felt
that it went too far. Their main objections were: there
had been no debate on the ethical acceptability of
these inventions; there might be an increase in the
livestock farmer's dependence on trade and industry;
it might lead to a further decline in the genetic diver-
sity of livestock; it could have negative effects on
developing countries, unless intellectual property is
well-protected in the developing country itself; and it
may have a limiting effect on research. After having
reviewed these various arguments, NOTA concluded
that there are three options open to Parliament (NOTA
1991a, pages 58-59):
• to adopt the draft directive (which would help to
harmonise national legislation);
• to reject it (which would block consistent
legislation);
• to amend it, accommodating those aspects that
have aroused criticism.
In 1992, NOTA continued with this difficult dilemma
of facing both international competition and national
lack of consensus. First, the agency prepared a com-
parative study about legislation and regulations on the
genetic modifications of animals. It reviewed the
situation in the European Commission, the Nether-
lands, the United Kingdom, Germany, Denmark,
France and the USA. It underlined differences among
countries, but also similarities among Denmark, Ger-
many and the Netherlands, which all three appeared
to be more reluctant with regard to genetic modifi-
cations of animals, when modifications are aimed
at the production of meat and milk rather than at the
production of medicines (NOTA 1992a).
Second, NOTA tackled the issue of understanding
the most important ethical and legal aspects for gov-
ernment policy. It defines ethics as "the philosophical
scientific discipline which systematically studies
ethical aspects, norms and values". The report then
goes on to state that the analysis of emotions is of
significance for government. In cases ofconflicts, the
government would have three options: to delegate
ethical decisions to an ethics committee (proce-
duralism); to settle the conflict by adopting the prin-
ciple of majority (democratism); to emphasise the
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right of freedom of its citizens (liberalism) (NOTA,
1992b).
Last, but not least, the agency published a study on
biotechnology and small-scale farmers-in developing
countries. The question which motivated the study
was how to improve those farmers' situation. AI-:
though biotechnology had a strong potential for that
purpose, traditional technology transfer was consid-
ered less helpful than an "interactive bottom-up" ap-
proach including small farmers in the process from
the very beginning (NOTA, 1992c).
In 1993, NOTA adopted the Danish method and
held a consensus conference (called "public debate")
on the subject of genetic modification of animals.
This was organised in collaboration with a private
institute for consumer research, and an institution
promoting the public understanding of science and
technology and funded by the Dutch Ministry of
Science and Education and the Ministry of Economic
Affairs. The main conclusions of the debate were
(NOTA, 1993a):
• a majority of the lay panel would like a moratorium
on the genetic modification of animals;
• they think that lay people should be consulted more
often;
• they call on the Ministry of Economic Affairs to
have a "more critical-ethical" policy;
• they would like alternative technologies to be
promoted. .
During the same year, NOTA prepared a report for
Parliament. It recalled that there are still diverging
attitudes in the country with regard to the accept-
ability ofgenetic modification, and that various social
groups are exerting pressures on politicians and gov-
ernment. The report stated that government should
avoid both ideological interference and moral indif-
ference, which would not do justice to the public
concern (NOTA, 1993b).
Change ofname
In 1994, NOTA changed its name to the Rathenau
Institute. Its stated mission was clearly (Rathenau
Institute, 1995a, page 9):
"to contribute to the social debate and political
opinion forming on issues that are the result of,
or are concerned with, scientific and techno-
logical developments, including the ethical
aspects of these developments."
Another aspect of its mission was (Rathenau Institute,
1994, page 33):
"to stimulate the learning process in order to
integrate social considerations into the develop-
ment and selection process of products ... the
results should form the basis for the formulation
of specific points for the biotechnology policy
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of the Ministry of Economic Affairs and the
Ministry of Agriculture, Natural Resources and
Fisheries." .
Where are lve going?
In 1995, the Institute organised a public debate (a
consensus conference) on Predictive genetic research,
where are we going? in collaboration with the Plat-
form for Science and Ethics, an official forum for
organising debates on science and technology (Mayer
et aI, 1995). The lay panel admitted that predictive
genetic research may provide solutions to human
suffering, but it insisted on limiting it all the same: it
wanted to avoid excessive diagnostic and medical
techniques, fearing that these techniques might deter-
mine whether someone is perceived as healthy or not.
The panel also would like to see ethics and ethicists
more actively involved in the development of the
research; it even called on a control, by ethicists and
central government, on fundamental genetic research
(Rathenau Institute, 1995b). Without clearly defining
who ethicists are and what is the basis for the legiti-
macy of their decisions, the lay panel seemed to
express somewhat authoritarian views.
At the same time, the Institute was busy adapting
an important European concept: Constructive Tech-
nology Assessment (CTA). Two reports appeared in
1995. Learning to Innova te (Rathenau Institute,
1995c) was submitted to Parliament and dealt with the
idea that technological development should be
guided. So did Biotechnology in Business. A Contri-
bution of Constructive Technology Assessment to
Biotechnological Innovation (Rathenau Institute,
1995d). Both reports tackled the issue of social accept-
ance of genetic research applications, discussed the
theme of"societal embedding" ofthe new biotechnol-
ogy, and discussed the roles of government and par-
liament in preparing the market for biotechnological
products (for example, by initiating dialogue with
social organisations at an early stage).
Germany
Germany shared a special feature with Denmark and
the Netherlands. Eurobarometers, that is, Union-wide
surveys of public opinion, had shown all through the
80s that risk perception increases as one goes from
south to north. The attitude of the German public
towards biotechnology was rather critical; at the same
time, the level of its knowledge seemed quite high
(Science Museum, 1992). As the Dutch TA agency
underlined in one of its recent reports (NOTA 1992a,
36):
"compared to the French or to the English, the
Germans showed more inclination to think that
biotechnological research and especially gene
technological research should be supervised by
the government; in the German Parliament, this
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In Germany, the executive and
legislative branches had shown
concern for biotechnologies all
through the 80s: hearings were
conducted with domestic and foreign
experts on issues such as scientific,
technical, environmental and social
risks
critical attitude was defended by the Greens and
the Social-Democrats, at least in the eighties."
In fact, both the executive and legislative branches
had already shown concern for biotechnologies all
through the 80s. Hearings were conducted with do-
mestic and foreign experts on issues such as scientific,
technical, environmental and social risks. In 1987, a
Commission of Inquiry (Chances and Risks of Gen-
etic Engineering) of the Parliament recommended
that safety guidelines were made legally binding. A
legislation process started in 1989, and a German
Gene Law was adopted in May 1990 (Gloede, 1997).
Safety
At the beginning of the 90s, a TAB study was con-
ducted on Biological Safety in the Use of Genetic
Engineering (cited in Gloede, 1992). This report con-
tains the findings of an international comparison on
regulation practices. Although a Gene Law had been
passed in May 1990, providing for substantial and
procedural measures to ensure biological safety in
research and commercial activities, there were good
reasons for the study to be made. The Commission of
Inquiry, appointed by the Bundestag in 1984, had
already dealt with safety guidelines for genetic
engineering, but the members of the Commission
knew that the topic was still important in the public
controversy.
The question of the proper 'safety philosophy' in
the assessment of the risks had remained largely un-
resolved. So had the issue of the social acceptability
of these new techniques. When the study began in
1990, biological safety was criticised as being too
narrow by both advocates and opponents of genetic
engineering. The advocates wanted to underline the
benefits, and not only the risks, of the new biotech-
nologies; while the opponents wished to stress poten-
tial social and political effects or risks (Gloede, 1992,
page 275).
In 1992, an interim report was discussed. Its scien-
tific basis was questioned, mainly with respect to the
views expressed by the representatives ofthe ecologi-
cal risk concept; those views were considered rather
untrustworthy, given the context of international sci-
entific discussion (note that, since the 1990 election,
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the Greens were no longer represented in the
Bundestag). At the same time, and more generally, the
German Gene Law was criticised as potentially
threatening the role of Germany as a leading country
for science and industry: there was no lack, but an
excess, of regulation, said the critics.
According to one analyst, the TAB study on bio-
logical safety was different from other TA studies
(Gloede, 1992, page 276):
"it is not simply aimed at enlightening decision-
makers and the public by compiling and if
necessary popularising available knowledge in
a study. It rather proceeds from the existence of
a multi-layered controversy on the topic and
attempts to identify areas ofboth consensus and
dissent, and also to describe alternative options
for the legislative."
This effort, however, was not totally successful, inso-
far as communication between groups holding di-
verging views was sometimes very difficult indeed.
Scientists (especially molecular biologists) tended to
interpret controversies in terms of incompetence;
politicians, in terms of impracticability; and for other
antagonistic social groups, the whole TA process
appeared illegitimate, endangering their interest or
moral standards (Gloede, 1992, page 276). The final
report on safety was published in 1993: it discussed
options for the organisation of safety research and for
legal regulation (Gloede, 1997).
Genetic mapping
Parallel to this analysis on safety, TAB conducted a
study on Genetic Mapping - Opportunities and
Risks ofGenetic Diagnostics. The report was publish-
ed in 1993 (TAB, 1993a). It recommended legal regu-
lation in fields such as: criminal justice, health and
life insurance, employees and places of work, health
system. However, the recommendations have not
been followed by legislative decisions so far. A moni-
toring process on gene therapy has been set up
(Gloede, 1997).
As a reaction to the controversies which were still
going on, the Committee for Research, Technology
and TA wished to expand the TAB inquiry. The
agency was given the mission to monitor trends in the
TA landscape. One report was completed in July 1993
(TAB, 1993b). It is an interesting review and evalu-
ation of selected foreign parliamentary TA studies.
With respect to new biotechnologies, the report
underlines first that technology assessment agencies
have been most active in Germany, Denmark, the
Netherlands and the United States. A majority of
studies deal with the application of biotechnology in
general, or with its application to agriculture, or with
its application to humanity (health, criminal law, gene
mapping); a few studies deal with its possible appli-
cation to the environment. The TAB analysts se-
lected: an O'TA report on global economy; a Dutch
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report, a Danish one, and an American one on
agriculture; a POST report and an O'TA report on
patenting DNA, a NOTA report and a STOA one on
bioethics'(T'Als, 1993, pages 1-3).
The TAB review of those various studies gave a
good overall picture of the situation. The issue of
commercial biotechnology and its fields of applica-
tion appear as key issues for the years to come, The
health sector opens a large market for this new tech-
nology, and so does the need for pharmaceutical
products; in addition, in most countries, public accep-
tance is fairly high with regards to using biotechnol-
ogy for improving diagnoses, therapies and health.
Applications to agriculture and food production are
still in the development stage. Besides, some
applications have been strongly criticised, namely by
consumers associations. Nevertheless, the potential
for quality improvement in that field should not be
underestimated, even though special attention should
be given to the delicate situation of small farmers and
of developing countries. Likewise, applications of
genetic engineering seem still very limited for the
moment, and the issue ofgenetically 'modified organ-
isms raises problems of social acceptance in many
places (TAB, 1993, page 39).
As far as the international economy was concerned,
the TAB report made things quite clear. It underlined
that Europe is likely to face hard competition with the
United States and Japan: the regulation climate is
indeed quite restrictive on the 'Old Continent', espe-
cially in northern Europe and Germany, and it is
marked by uncertainty. Intellectual property and pat-
ents are key factors in the development ofcommercial
biotechnologies. In some countries (such as USA),
patent protection is rather extensive. Harmonising
international regulations will become a pressing need,
in view of both commercial exchanges and scientific
collaboration (for instance, in the framework of the
Human Genome Project) (TAB, 1993, page 40).
Finally, the TAB report tackled the question of the
risks and consequences of new biotechnologies. Al-
though risks are mentioned quite often in debates, the
authors noted that very little is known as to what those
risks really are. Nevertheless, various applications of
genetic engineering have been judged as dangerous
from the ethical point of view. In a similar vein,
critical opinions have been expressed by groups, in
northern and central Europe. In this case, the differ-
ence is striking with the United States, Southeast Asia
or southern Europe where public perceptions are more
positive on the whole, especially when genetic engi-
neering is aimed at health improvement (TAB, 1993,
page 41).
Health issues
At the same time, TAB got actively involved in health
issues. Two reports dealt with monitoring gene ther-
apy. The first was published in 1993 (TAB, 1993c)
and explained the scientific and medical state-of-the-
art in the development of genetic therapeutic
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methods. On the one hand, this development gave rise
to great expectations with respect to the treatment of
serious diseases (such as cancer and AIDS). On the
other hand, the risks of those methods for the patients
are not very well known yet.
The TAB report described the gene transfer pro-
cess. It then went on to summarise the controversies
that had taken place about the dangers of the process,
and the current opinions of the German specialists,
classified into four groups (from those who prefer
viral vectors for a rapid development of genetic ther-
apy, to those who are against any method, for safety
reasons, except in cases of diseases which have no
alternative treatment) (TAB, 1993c).
The whole exercise was meant to help the members
of the Bundestag to bring in legislation to that field.
As promised at the end of the first report, TAB pub-
lished a second analysis in 1996, focusing on legisla-
tion and regulations abroad (TAB, 1996). It reviewed
the situation at length in France, the United States, the
United Kingdom, the Netherlands, Italy, Austria, and
to a lesser degree, in smaller European countries and
Japan. It indicated that the patients' safety and the bio-
logical safety were taken quite seriously everywhere.
The analysts found various tentative solutions in
those countries, dealing with potential safety prob-
lems: severe criteria for applications of gene therapy;
ethics committee to be consulted; regulations (with
respect to clinical research, to cost-benefit analysis,
to patient enlightenment and free consent, to public
and penal liability). The report also drew the reader's
attention to the European dimension of the issue, and
to the need for the Union to be more innovative in that
field (TAB, 1996).
Developing countries
TAB tackled another question at great lerigth recently.
In 1995, a report was published on the effects of
modem biotechnologies on developing countries and
consequences for the future collaboration between
industry and developing countries (TAB, 1995). The
project was initiated in February 1994 by the Com-
mittee for Economic Collaboration and the Commit-
tee for Education, Research, Technology and
Technology Assessment of the Bundestag. Its overall
objective was fairly ambitious: to examine how new
biotechnologies could contribute to solving some
problems of the developing countries, or to examine
at least how the gulf between rich and poor countries
could be stopped from widening.
The analysts first drew up a list of fields of appli-
cation for biotechnological research: agriculture and
food production (Germany had already promoted
more than 100 research projects of that kind between
1988 and 1994); health; resources protection; and
conservation. The report then went on to examine the
case of developing countries in the international con-
text. It finally indicated options for politicians inter-
ested in dealing with third world questions.
Three issues have been singled out, one of which
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was intellectual property and patent regulations. It
was suggested that positive impulses should be given
to developing countries, in the spirit of an argument
developed by some international third world groups:
it should be made possible to protect the indigenous
knowledge ofmedicine or food production. The sec-
ond and third issues were biological safety and gen-
etic resources; both were in need of an international
protection concept. In conclusion, biotechnologies
could have potential positive effects on developing
countries, provided they were adapted (for instance,
oriented to the needs of small farmers, the promotion
oflocal research, or the promotion ofwomen and their
contribution to innovation) (TAB, 1995).
United Kingdom
Since the beginning of the 90s, POST has prepared
various studies and notes with regard to biotechnol-
ogy. Patenting was one of the first important issues.
It was dealt with in two steps: one study focused on
patenting life, generally speaking; another tackled the
patenting human DNA.
Patenting
Patenting Life (POST, 1991) seemed to handle the
issue differently from the way it was handled in
Denmark and the Netherlands. POST avoided taking
sides in the ethical debate, but it gave as much inform-
ation as possible to let Members of Parliament make
their own judgement. The briefing note was espe-
cially worthy of comment: its conciseness made the
message altogether enlightening for Members or for
any citizen interested in those matters.
The note briefly explained the developments which
have led to issues relevant for legislators. It first
summarised the scientific aspects, simply and clearly,
about how recombinant DNA technology can modify
the basic genetic makeup of a living organism. It
described the key steps in genetic modification and
indicated the patentable ones (gene identification and
isolation, identification and isolation method
development, transfer of gene construct into living
organism).
The report reviewed the patent laws in various
countries; it showed differences, but also some simi-
larities (all countries require that inventions demon-
strate the characteristics ofnovelty, inventiveness and
utility); in addition, the readers were informed that the
European Commission had prepared a draft directive
which would facilitate the patenting of genetically
modified plants and animals.
The analysis then went on to explain current con-
troversies. From a legal and/or scientific point of
view, debates focused on: how far a patent can be
applied to whole organisms; how far genetic engi-
neering can be considered as an inventive activity
(demonstrating novelty, and so on) since gene transfer
may be perceived as a natural occurrence; how far
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American policy-makers argued that
investment of public funds should
lead to products and services to
benefit the USA: the quarrel has
undermined the spirit of international
scientific collaboration which was the
basis of the human genome project
intellectual property protection, in that field, should
be broad or restricted. From a religious and/or moral
point of view, patenting is sometimes criticised as
being equal to granting ownership of life forms, which
either should not be considered as available for appro-
priation and exploitation, or should be viewed as the
common heritage of humankind (POST, 1991). It is
noticeable that POST's style was to present a bal-
anced view of the pros and cons, and to describe
controversies without arbitrating on them.
POST dealt with Patenting Human DNA a little
later (POST, 1992). The report first explained that the
problem had arisen within the context of a large
international programme of scientific collaboration,
aimed at decoding the human genome. The inter-
national programme is composed of a number of
national programmes, primarily in the USA, France,
Germany, Japan and the UK; the European Union too
partly supports European researchers. Co-ordination
between the programmes is assisted by the Human
Genome Organisation (HUGO), which was estab-
lished at the end of the 80s and consists of 500
research groups. Decoding the human genome is an
enormous enterprise, with potential consequences for
both commercial development and scientific under-
standing of gene functions.
POS]' had good reasons to deal with patenting life
and patenting human DNA in two different steps.
There had been controversies with respect to both
issues, but the meanings and the stakes were not quite
similar. In the hurnan I)NA case, there was a potential
conflict between advancing scientific knowledge
through international collaboration and protecting
national economic interests.
American policy-makers did not want knowledge-
producing projects to be easily commercialised by
other countries. They argued that investment ofpublic
funds should lead to new products and services to the
benefit of the lJSA; this is why the US National
Institute of Health claimed, in 1991, to deposit patent
applications for the basic data from their DNA pro-
gramme. The previous practice of publishing partial
sequence data was seen as a threat to the patentability
of whole genes in the future. It was therefore a threat
to companies' investment to explore potential
applications of the new knowledge.
This attitude had been opposed by scientists
outside the USA, and by many inside as well. An
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important argument of the opposition was that this
approach was unprecedented because it attempted to
patent sequences of genes or parts of genes, whose
functions have not been identified. French scientists
have also argued that the basic sequence of human
DNA is part of the scientific heritage of humankind;
therefore it cannot be appropriated by anyone.
The quarrel has already undermined the spirit of
international scientific collaboration which was the
basis of the human genome project. Reluctantly, the
UK had adopted a defensive attitude too, striving to
protect national interests through patent application,
while all other participants in the project decided to
continue to make their partial sequence data available
without attempts at patent protection.
For the time being, this asymmetrical situation
tends to inhibit international co-operation. The UK
would therefore have two options: to pursue existing
policy or to withdraw the patent applications. POST
gave arguments for and against each option, and
reminded its readers that it is probably time to harm-
onise international patent laws (POST, 1992).
Pros and cons were also balanced with respect to
biofuels (alternatives to diesel and petrol that can be
made from certain agricultural crops). POST pub-
lished a note on Biofuels for Transport in 1993
(POST, 1993). -After some technical considerations,
the study reviewed arguments to judge whether bio-
fuels are more or less environment-friendly. It also
examined the European Commission policies related
to the issue, primarily recent agricultural reform
agreements and tax treatment.
European integration
The European integration process is fairly complex.
At times, this complexity per se justifies a study. A
good case in point was an assessment entitled Regu-
lating Biotechnology (POS']"', 1994). POST first de-
scribed the changing attitudes to regulation in Europe,
as far as the genetically modified organisms were
concerned. At the beginning of the 90s in the Union,
two key directives were regulating the use of genetic
modification and the release of modified organisms
in the environment. The Contained Use Directive
applied to microbial organisms and spgcified various
levels of containment. The Deliberate Release Direc-
tive applied to the release ofmicrobial organisms and
of larger ones such as plants. Both required a detailed
risk assessment and consent from the competent
authorities (in the UK, the Health and Safety Execu-
tive and the Department of the Environment).
By the time the Directives were implemented in
1992, there were serious doubts about their appropri-
ateness. Some questioned their consistency with up-
to-date scientific thinking, and argued that the risks
foreseen had been overestimated. In the UK, for in-
stance, the directives were reviewed by the House of
Lords Science and Technology Committee in 1993;
it concluded that the Directives were "excessively
precautionary".
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The same year, a European White Paper on Growth
Competitiveness and Employment concluded that
biotechnology was "amongst the most vigorous and
competitive sectors in the community", and the Com-
mission was asked by the German Presidency to re-
view the Directives in such a way as to simplify
notification and consent requirements. These changes
have been opposed by environmental groups who felt
concerned by deregulation.
Parallel to this regulatory debate, there was grow-
ing importance attached in the Union to procedures
for setting standards. The Directives' means ofimple-
mentation was through the laws of Member States.
This is why some variation among States took place
(for instance, Germany and Denmark had introduced
a stricter regime than France and Belgium which had
been quite liberal). A need was felt for interpretative
standards if measures were to be uniform across the
Union.
The European Commission thus decided, in 1992,
to commission the CEN (Centre Europeen pour la
Normalisation) to produce detailed standards (the
CEN consists of 18 national standards bodies within
the 'Old Continent'). In the formal request, the Euro-
pean Commission explicitly asked the CEN "to im-
prove competitiveness in Community and external
markets" (POST, 1994). Notice that POST did not
itself advocate promoting biotechnologies or regula-
tions, neither did it militate against them. It just
informed.
Consensus conferences
The UK also tried something very European: a con-
sensus conference was organised in 1994. The Danish
model was mentioned, but in contrast with the Danish
Board, and even more in contrast with the Dutch
Rathenau Institute, POST managed to maintain a
distance from the process. It just reported on it, in
1995, under the title Plant Biotechnology - a Consen-
sus? (POST, 1995). The British conference was
funded and organised by two agencies: one govern-
ment research council (the Biotechnology and Bio-
logical Sciences Research Council) which funded the
initiative; and the Science Museum which adminis-
tered the event, as an organisation involved in the
promotion ofthe public understanding of science, but
without special interest in biotechnology (Joss, 1995).
In its report, POST summarised what the lay panel
said. Potential benefits of plant biotechnology (such
as nutritional values, reduced use of fertilisers and
pesticides) were weighted against risks (such as dis-
ruption ofthe food chain, infringement ofplant breed-
ers' rights and undermining of traditional economies)
From the consumer's perspective, the panel felt that
the products were more the result of researchers and
producers creating a market, rather than the market
expressing a need or desire for them. On the environ-
ment, the panel noted that the impacts of plant
biotechnology are difficult to predict.
Generally speaking, POST concluded that the
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experiment was a success. Members of the panel
reported that they had learned a lot. And although
consensus conferences in the UK do not have the close
links to Parliament that they have in Denmark, the
process gave an insight into the kinds ofconcerns and
principles which were held by informed lay people
(POST, 1995).
France
The French office of technology assessment is the
oldest office in the European network, having been
created at the beginning of the 80s. Yet it did not get
involved in biotechnologies until the beginning ofthe
90s.
Agriculture andfood
The fist study related to those issues dealt with the
applications of biotechnologies to agriculture and
food industry (OPECST, 1990). The study was re-
quested by the parliamentary Committee of Produc-
tion and Exchanges. The request came at the right
time, as the introduction of the report made it clear:
the European Commission had just prepared two
Directives on the uses of recombinant DNA and
micro-organisms, and was in the process ofpreparing
other. The study was therefore meant to help French
parliamentarians to take a stance within the Union's
decision-making process. According to OPECST's
rules, the report was entrusted to one of its members,
who was also a Member of the Parliament.
The first question this person dealt with was: are
biotechnologies really new technologies or not? Is
there a revolution in that sector or simply an evolu-
tion? After a short but clear technical explanation, the
analyst concluded that human beings have always
contributed to natural selection since agriculture ap-
peared on earth. In that sense, the recent development
of plant improvement should not be interpreted as a
revolution. Nevertheless, modem techniques, and
particularly genetic engineering, lead to a real change
of scale as far as selection is concerned. They also
tend to suggest that humanity has a new power on life
processes.
The analyst went on to describe and weight various
uses of biotechnologies, their risks and benefits, for
plants, for breeding, for agribusiness, for energy pro-
ducing, for health sectors, for developing countries.
On the whole, potential benefits were evaluated as
important. Another problem was discussed at length:
the patent regulation. The study was quite informative
as to the history of regulations in various sectors
(plants, animals, man) and in various countries; it
dealt with ethical, economic and ecological stakes as
well.
The study ended with a series ofrecommendations.
It pleaded for a national debate on the issue:
biotechnologies should be "demythologised and
demystified" (page 85) in order to be perceived as a
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Options Assessment of the European
Parliament made it clear that its role
was simply to clarify the facts and
arguments for or against options, but
the options as such remain the
responsibility of the Ministers
progress rather than a threat. In the same vein, it was
suggested that information be improved in such a way
as to avoid anxiety; and it was expected that scientists
should communicate better about their activities.
Denmark was mentioned as an example where young
children get used to genetic engineering by doing
some simple experiments themselves. Other recom-
mendations dealt with improving French research in
the field, getting ready to legislate on patents, study-
ing the impact of genetic engineering on the environ-
ment, protecting genetic diversity.
Human rights
Biodiversity and Genotype's Protection was the
theme of a report pub Iished in 1992. 1 The same year,
OPECST dealt with another ambitious issue: life sci-
ences and human rights (OPECST, 1992). This ques-
tion was entrusted to a senator. The content was
actually closer to bioethics than to regular technology
assessment, insofar as it proposed great principles,
and sometimes asserted normative stances, instead of
simply providing information and exploring options.
The only point of agreement with the other
OPECST study was the need for more information
and debate. Most of the report dealt with biomedical
ethics related to assisted conception, antenatal diag-
noses, human body and human rights. In the introduc-
tion, it was suggested that France has a special status
in the history ofhuman rights and enlightenment, that
life sciences might threaten those rights, that Europe
should protect human dignity and assert great
principles.
European Parliament (STOA)
STOA was launched in 1987, initially for a trial period
of 18 months; then it was made permanent. To a large
extent, STOA reflects the evolution of the European
Parliament. The power and influence of this legisla-
tive body have slowly but surely increased (Corbett
et al, 1997). STOA was set up, officially, to provide
MEP (Members of the European Parliament) with
sources of information and advice, in order to address
complex scientific and technological issues.
From the very beginning, STOA made it clear that
it was not its job to define Parliament's position; its
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role was simply to clarify the facts and arguments for
or against options, but the options as such remain the
responsibility of the Members. This principle of self-
restraint is an important technology assessment prin-
ciple. It aims to restore the rights of a political
authority which a society highly dependent on science
and technology seemingly denies. It seeks, as it were,
to return politics to the politicians, after they have
been enlightened, while stressing that it is the Mem-
bers, not the experts, who have the last word. Inter-
estingly, this principle is more clearly stated by STOA
than by any national agency (except maybe the British
POST). It is, however, not easy to implement, as the
following examples suggest.
Bioethics
The report Bioethics in Europe was completed in
1992 (STOA, 1992). It aimed to provide an informed
basis on important questions for legislative processes
in this decade. The report presents an overview of the
ethical issues raised by the new biological and genetic
engineering technologies (such as human genome
analysis, prenatal diagnosis, genetic screening, gene
therapy, transgenic animals, patenting life forms, and
economics of biotechnology), and sets out the simi-
larities and differences between Member States in this
regard.
As far as the form is concerned, the report certainly
has qualities in terms of reader-friendliness: it is
prefaced by an executive summary which faithfully
reproduces the text and its conclusions, and permits
the reader to tum quickly to the topics concerned; the
topics are discussed on the basis ofa similar structure
(technical, ethical, social and legal aspects).
As far as the content is concerned, however, the
message is somewhat ambiguous. On the one hand,
the ethical assessments are not just catalogues of the
values and preferences of various groups; more often
than not, they seek to present "strictly moral" objec-
tions (for instance, page 95), generally on the subject
oflife forms, without a detailed account ofwhat gives
such objections their legitimacy. In the process, the
assessors tend to think on Members' behalf, instead
of simply clarifying matters so that they can make
their own choices. On the other hand, after being
given arguments on the potentially sacrilegious na-
ture of various technologies, MEPs are reminded to
promote the integrated market, and accordingly to
foster public acceptance ofbiotechnologies. Hardly a
coherent message.
Pharmaceuticals
From that perspective, another issue was dealt with
quite differently, one year later, in a report on new
pharmaceuticals substances (STOA, 1993). This
analysis illustrates an important service which an
assessment can perform for MEPs: to catalogue for
them the issues and interests at stake in the context of
a particular technological development. In this case,
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there is both a technical assessment of the innovative
nature of certain medicines, and an assessment of the
social, economic and political implication thereof.
The study highlights both the conflicts of interest
and the potential alliances; it provides some tools for
mastering the complexity of the issue on both the
technical and the human level. The study gives promi-
nence to specifically European characteristics: har-
monisation of national legislation (and hence,
indirectly, subsidiarity), and support for the European
industry in the face of the globalisation of the econ-
omy. This is no scant result, as STOA is uniquely
well-positioned to analyse the distinctive European
(as opposed to individual country) dimensions of the
issues it addresses.
Biotechnologies and developing countries
In 1994, STOA dealt with biotechnologies and dev-
eloping countries. Two reports appeared simultane-
ously: Biotechnology and Cereal Production for
Developing Countries (STOA, I994a) and The Effect
ofPatent Protection on Plant Biotechnologies in Dev-
eloping Countries (STOA, 1994b). Obviously, both
issues are important and relevant for MEPs; both
studies highlight technical processes, and their rela-
tionship to political problems.
The first one analyses the production of maize,
rice, sorghum and millet by resource-poor farmers in
Sub-Saharan Africa, and the role of women, who are
key actors in African fanning systems. The study is
aimed at helping MEPs in the context of possible
restructuring ofbiotechnology research and develop-
ment policies and budgets in the European Union.
The patent study, as well, points towards a distinc-
tively European point ofview. After explaining what
a patent is, why some developing countries want
patent protection and some do not, and what the
international agreements on intellectual property
rights are, the study sets the current European stance
and the process of making directives, and amending
them, by the Commission, the Council and the Parlia-
ment. The European Parliament has intervened in the
process (for instance, in 1992), and recently (1998)
adopted the amended Directive on patenting life, in-
cluding, for instance, the "farmer's privilege" (that is,
re-sowing seeds which were originally subject to
patent protection).
In spite ofits rather short experience, STOA seems
to be catching up with its ambitious goal of helping
to formulate European policies. For that matter,
MEPs appear quite conscious of the potential useful-
ness of the agency and concerned to improve its
quality (see, for instance, the evaluations recently
requested: Westermeyer, 1994; Armand, 1998).
Concluding remarks
If we attempt to set the various reports mentioned
above in a comparative perspective, the 'most
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different difference' seems to be between the 'Old'
and the 'New' Continent. Even though there are some
differences among the national studies from Europe
(the topics they focused on, the recommendations
they make), those differences are somewhat over-
shadowed by common features that European TA
agencies share, in contrast to the American situation.
The US Congress O'TA produced its main reports
on biotechnologies by the end ofthe 80s. Not only
was it the first legislative agency to deal with such a
complex topic, but it dealt with it in quite an inform-
ative way for legislators. The issues were broad and
varied, ranging from commercial biotechnology,
international trade, changing agriculture, risk assess-
ment, and basic research to more social, political or
even philosophical problems, such as public percep-
tions ofbiotechnologies, ownership ofhuman tissues
and cells, or patenting life. This was a breakthrough
as far as biotechnology assessment is concerned.
The European TA agencies did tackle the same
issues, directly or indirectly, a little later, from the end
ofthe 80s on. Yet, for the time being, the core concern
underlying these studies seems to have more to do
with how to promote biotechnologies without meet-
ing too much popular resistance.
Various reasons may account for this core concern.
On the one hand, the technology assessment question
has been monopolised for a long time by the executive
branches ofthe governments, the Union's administra-
tion and various academics and researchers; parlia-
ments have been rather passive until recently and
seem to be still in the learning process. On the other
hand, the European Union has adopted a policy
strongly promoting scientific and technological co-
operation across countries since the mid-Sus; such a
policy is expected to help to accelerate political inte-
gration, indirectly but efficiently.
These peculiar conditions are perhaps partly re-
sponsible for some characteristics appearing in most
European studies. All countries are concerned by the
European Commission Directives with respect to
biotechnologies and genetic engineering: all agencies
give information about that matter, and most of them
attempt to take a stance about the actual regulations.
They share the view that it will be necessary to
harmonise national legislation in the not too distant
future. They look to assess national competitive ad-
vantages in that technological field, sometimes in a
rather elaborate way: for instance, the Danish study
on green biotechnologies, or the more recent German
study on collaborating with developing countries.
Another issue which appears to be a special matter
of concern for Europeans is 'social acceptance' or
'social acceptability' of biotechnologies. This might
be the other side of the coin. A part of the public was,
and still is, rather critical towards these techniques,
especially in Germany, Denmark and the Nether-
lands. The fact is somewhat in conflict with the need
to promote national and European industries to be
competitive in the international arena. These
contradictory conditions give an ambiguous flavour
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to the notion of 'social acceptance': it is supposed to
express a democratic concern, but it also sounds like
a down-to-earth marketing device.
Within the European network, there are a few
differences as well. With respect to style, for instance,
the British POST displays a sense of balance and
impartiality, close to the spirit pioneered by OTA
(" ...neither to promote nor to discourage the develop-
ment of any particular technology or legislation... ").
POST just strives to clarify, without taking sides,
scientific and technical questions, controversies, or
the complexity of the European integration process.
Consensus conferences constitute another source
of difference. between European TA agencies. They
demonstrate the will to involve regular citizens in
technological debates. The idea was pioneered by
Denmark, adopted by the Netherlands and, to a lesser
degree so far, by the United Kingdom. Consensus
conferences have focused mainly on genetic engi-
neering on animals and humans (predictive genetic
research).
To judge their results is not an easy task. Indeed,
the concept is rather ambiguous. On the one hand, it
seems to surpass the democratic concern of parlia-
mentary TA by going down to regular citizens. On the
other hand, the experiences are disconcerting and
challenge precisely this good intention. More often
than not, popular juries express authoritarian views
(for instance, lay panels requesting that ethicists con-
trol fundamental genetic research, without clearly
defining who ethicists are supposed to be and what is
the basis for the legitimacy of their decisions).
In addition, the legitimacy of the lay panel's opin-
ions may be questioned, as it is neither elected nor
statistically representative of the society, especially
when the consensus conference has an impact on a
political decision (for instance, the Danish Parliament
decided not to fund animal gene technology projects
in the biotechnology research and development pro-
gramme 1987-1990, as a consequence of the 1987
conference).
Notes
1. This report was no longer available at the time of this research.
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